TNFRSF9 and neoplasm: More importantly, a 4-1BB agonist has been shown to exert antitumor effects in not only immunogenic tumor models, but also nonimmunogenic models; this is very relevant for DIPGs, because they are nearly devoid of infiltrating lymphocytes and present very few mutations (10–12).